Prezista (Darunavir) Patent Expiration, LOE Window & CMS Spending
Prezista (Darunavir) by Johnson & Johnson: FDA Orange Book core substance LOE 2027-06-26, 10 AB generics, $44.4M 2024 CMS Part D & Medicaid spend, and 10 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Johnson & Johnson |
| FDA Application & Pathway | N021976 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | 2027-06-26 |
| Last Listed Patent or Exclusivity Date | 2027-06-26 |
| Orange Book Patents (*PED Extensions) | 2 patents (1 *PED) |
| Active AB-Rated Generic Competitors | 10 |
| 2024 CMS Total Public Spend | $44.4M |
| 2024 Medicare Part D Spend | $24.7M |
| 2024 Medicaid Spend | $19.6M |
| Reported Wholesale Price Change (CA SB 17) | 10 WAC filings (max 18.7% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.